Walgreens Reinvents Nation’s Largest Health and Wellbeing-centered Loyalty Program with myWalgreens to Offer Customers Many More Benefits
19.11.2020 16:00:00 EET | Business Wire | Press release
Walgreens today announced the launch of myWalgreens, a complete reinvention of its customer loyalty program to offer customers extensive new benefits, including the fastest same-day retail pickup offering available today*. Customers can now shop online and on a fully-redesigned mobile app for health and wellness items, and then pick them up in the store, curbside or at the drive-thru in as little as 30 minutes.**
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005676/en/
Walgreens pickup at curbside (Photo: Business Wire)
Walgreens has the nation’s largest health and wellbeing-centered customer loyalty program, with more than 100 million members. It’s now easier than ever for its members to stay well, shop conveniently and save money and time seamlessly across more than 9,000 stores, Walgreens.com and the mobile app.
The new benefits are in addition to many others already offered by Walgreens. These include an at-home delivery service through DoorDash and Postmates and a Prescription Savings Club with up to 80 percent off cash retail prices.
myWalgreens members can sign up quickly and easily for no cost, and will now receive:
- One percent Walgreens Cash rewards storewide
- Five percent Walgreens Cash rewards on Walgreens branded products
- “Only for you” exclusive deals
Additionally, the mobile app now features a broad range of health and wellness services for customers and patients, including a 24/7 pharmacy chat, access to find and book medical care and vaccination appointments, personalized health and wellness advice, real-time flu alerts and more. The previous version of the app is already very popular, and has been downloaded more than 65 million times.
“As America’s community pharmacy, Walgreens is delivering an unparalleled experience to help customers and patients manage their health and wellbeing during the most severe health crisis of our lifetimes,” said John Standley, Walgreens president. “As always, our more than 25,000 community pharmacists remain at the core of our offering. Our pharmacists and patient care teams do far more than just filling prescriptions – they provide trusted advice, personalized support and a vast range of services.”
The debut of myWalgreens marks another milestone in the company’s digital transformation. Walgreens delivers customers more and more benefits and a highly-personalized experience by working with the very best technology and customer-insight partners, including Microsoft, Adobe and Epsilon.
Online or on the app, myWalgreens members can:
Save Time and Increase Convenience
- Shop a full assortment of more than 27,000 items, including everyday health and wellness and over-the-counter essentials, as well as photos
- Add a payment method to their digital wallet for faster contactless checkout
- Redeem Walgreens Cash rewards instantly at checkout
- Choose digital receipts for quick contactless checkout and to track purchases
Stay Healthy
- Earn bonus Walgreens Cash rewards for achieving health goals
- Receive daily, personalized recommendations for health and wellness, as well as real-time local environment and health forecasts
Help Communities
- Donate their Walgreens Cash rewards to charity (the eligible charity organizations will rotate, beginning with the Full Plate Project, a program of Comic Relief U.S.’ Red Nose Day which works to end child poverty)
Starting today, current Walgreens Balance Rewards members can transfer their membership to myWalgreens at mywalgreens.com. Current Balance Rewards members have until January 31, 2021 to sign up for myWalgreens to ensure that existing rewards roll over to the new program. Over the next several months, myWalgreens will announce even more benefits for customers and patients.
Click here for myWalgreens press kit, including a logo, images and app screenshots.
About Walgreens
Walgreens (www.walgreens.com) is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), a global leader in retail and wholesale pharmacy. As America’s most loved pharmacy, health and beauty company, Walgreens purpose is to champion the health and wellbeing of every community in America. Operating more than 9,000 retail locations across America, Puerto Rico and the U.S. Virgin Islands, Walgreens is proud to be a neighborhood health destination serving approximately 8 million customers each day. Walgreens pharmacists play a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services. To best meet the needs of customers and patients, Walgreens offers a true omnichannel experience, with platforms bringing together physical and digital, supported by the latest technology to deliver high-quality products and services in local communities nationwide.
* As compared to national omni-channel food and pharmacy mass retailers that offer store pick-up free-of-charge.
** For Walgreens store locations that are not open 24 hours, orders must be placed at least one hour prior to store closing in order to be eligible. Otherwise, order will be ready the following business day. Customer will be notified via email when order is ready for pickup and will be provided instructions for a drive-up experience that complies with social distancing guidelines. Orders are not guaranteed to be ready within the 30-minute time window and may be subject to change or substitution depending on product availability at the time order is placed. Orders with age-restricted items may only be picked up in store. Prescription orders not eligible but may be ordered through Walgreens Express®. To find the location and hours of a Walgreens store near you, visit Walgreens.com/FindAStore.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005676/en/
Contact information
Walgreens PR Contact:
Emily Hartwig-Mekstan
emily.hartwig@walgreens.com
Walgreens Boots Alliance PR Contact:
Morry Smulevitz
morry.smulevitz@walgreens.com
Investor Relations:
+1-847-315-2922
http://news.walgreens.com
@WalgreensNews
facebook.com/Walgreens
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom